| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
This compound specifically targets the oxytocin receptor (OXTR), a class A G-protein coupled receptor (GPCR). It acts as a potent antagonist, blocking the binding of the endogenous neuropeptide oxytocin. Its pA2 value is 7.35 +/- 0.08, indicating high antagonist potency. By blocking this receptor, the compound can inhibit oxytocin-mediated signaling pathways. It also competitively inhibits the contraction induced by arginine vasotocin (AVT).
|
|---|---|
| ln Vitro |
In cell-free receptor binding assays, (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin has a pA2 value of 7.35 +/- 0.08, indicating its high potency as an oxytocin receptor antagonist. This binding affinity is determined by its ability to inhibit oxytocin-induced downstream effects. The peptide has no intrinsic agonist activity, making it a pure antagonist that is useful for studying the blockade of the oxytocin receptor.
|
| ln Vivo |
Specific in vivo activity data is not detailed in standard databases. However, the compound has been used to support the hypothesis that pituitary secretion of oxytocin is associated with coactivation of centrally projecting brain oxytocin pathways, some of which are causally linked to induced inhibition of food intake. By blocking oxytocin receptors in the brain, this antagonist can reverse oxytocin-mediated behavioral effects, such as satiety or social recognition, in rodent models. In vitro, it inhibits arginine vasotocin (AVT)-induced contraction.
|
| Enzyme Assay |
The standard protocol for assessing oxytocin receptor antagonism involves a competitive radioligand binding assay using membrane preparations from cells expressing the human oxytocin receptor. Membranes (30 ug) are incubated with [125I]-OVT (oxytocin) as the radioligand (0.1 nM) and increasing concentrations of the unlabeled test compound (1 pM to 10 uM) in binding buffer. After a 60-minute incubation at room temperature, bound radioligand is separated by vacuum filtration through GF/C filters pre-soaked in 0.3% polyethyleneimine. Non-specific binding is determined in the presence of 10 uM unlabeled oxytocin. Radioactivity is measured, and Ki values are calculated.
|
| Cell Assay |
For an in vitro cell-based functional assay, HEK-293 cells stably expressing the human oxytocin receptor and a CRE-luciferase reporter gene are used. Cells are seeded in 96-well plates and cultured for 24 hours. The cells are then pre-incubated with varying concentrations of (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (0.1 nM to 10 uM) for 15 minutes, followed by stimulation with oxytocin (1 nM, EC80). After 5 hours, luciferase activity is measured using a commercial one-step luciferase assay system. The antagonist activity is quantified as the concentration that produces a 50% reduction (IC50) of the oxytocin-induced luciferase signal, and pA2 values are derived using Schild regression analysis.
|
| Animal Protocol |
An in vivo protocol for assessing oxytocin antagonism involves central administration into the brain of rodent models. Male Sprague-Dawley rats are surgically implanted with a guide cannula targeting the lateral ventricle. After a 7-day recovery period, (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin is dissolved in artificial cerebrospinal fluid (aCSF) and administered intracerebroventricularly (ICV) at doses of 1-10 ug/rat. Control rats receive vehicle (aCSF). Thirty minutes after ICV injection, rats are given an intraperitoneal injection of oxytocin (0.1-1 mg/kg). Behavioral assays, such as food intake measurement or social interaction tests, are then conducted. Antagonism is quantified as the reversal of oxytocin-induced behavioral effects.
|
| ADME/Pharmacokinetics |
Detailed PK data for this peptide antagonist is not available. As a synthetic cyclic peptide, (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin is expected to have poor oral bioavailability and a short plasma half-life due to proteolytic degradation. When administered directly into the CNS (e.g., by ICV injection), it can achieve high local concentrations in the brain, bypassing systemic clearance. Its stability is enhanced compared to native oxytocin due to the presence of non-natural amino acid substitutions.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for this peptide is not available. As a research peptide that is typically administered locally (e.g., ICV), systemic toxicity is expected to be low at the doses used. However, because oxytocin receptors are widely distributed and involved in parturition and milk ejection, systemic administration of a potent antagonist could potentially disrupt reproductive functions. Peptide antagonists generally have a low immunogenic potential, but this is not a concern for acute research applications.
|
| References | |
| Additional Infomation |
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is a research-grade chemical and is not approved for clinical use. Its molecular weight is 1075.32, with a molecular formula of C48H74N12O12S2. It is provided as a lyophilized powder and stored at -20degC. The structural modifications include a d(CH2)5 substitution at position 1, a Tyr(Me) at position 2, and an Orn at position 8, which confer potent antagonist activity and increased stability. This compound is a key tool for studying oxytocin receptor function in neurobiology.
|
| Molecular Formula |
C48H74N12O12S2
|
|---|---|
| Molecular Weight |
1075.30
|
| Exact Mass |
1074.499
|
| CAS # |
77327-45-8
|
| PubChem CID |
71312201
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1537.6±65.0 °C at 760 mmHg
|
| Flash Point |
883.7±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.625
|
| LogP |
-2.55
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
74
|
| Complexity |
2010
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
S1C2(C([H])([H])C(N([H])[C@]([H])(C(N([H])C([H])(C(N([H])[C@@]([H])(C([H])([H])C([H])([H])C(N([H])[H])=O)C(N([H])[C@@]([H])(C([H])([H])C(N([H])[H])=O)C(N([H])[C@]([H])(C(N3C([H])([H])C([H])([H])C([H])([H])[C@@]3([H])C(N([H])[C@]([H])(C(N([H])C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])N([H])[H])=O)=O)C([H])([H])S1)=O)=O)=O)[C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])=O)C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])OC([H])([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])C([H])([H])C2([H])[H]
|
| InChi Key |
ZWVZXPFUQHTUKV-SZQHDTAUSA-N
|
| InChi Code |
InChI=1S/C48H74N12O12S2/c1-4-27(2)40-46(70)56-31(16-17-36(50)61)42(66)57-33(23-37(51)62)43(67)58-34(47(71)60-21-9-11-35(60)45(69)55-30(10-8-20-49)41(65)53-25-38(52)63)26-73-74-48(18-6-5-7-19-48)24-39(64)54-32(44(68)59-40)22-28-12-14-29(72-3)15-13-28/h12-15,27,30-35,40H,4-11,16-26,49H2,1-3H3,(H2,50,61)(H2,51,62)(H2,52,63)(H,53,65)(H,54,64)(H,55,69)(H,56,70)(H,57,66)(H,58,67)(H,59,68)/t27-,30-,31-,32-,33-,34-,35-,40-/m0/s1
|
| Chemical Name |
(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(10R,13S,16S,19S,22S)-13-(2-amino-2-oxoethyl)-16-(3-amino-3-oxopropyl)-19-[(2S)-butan-2-yl]-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9300 mL | 4.6499 mL | 9.2997 mL | |
| 5 mM | 0.1860 mL | 0.9300 mL | 1.8599 mL | |
| 10 mM | 0.0930 mL | 0.4650 mL | 0.9300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
